Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.

ABSTRACT:

Introduction

Type 2 diabetes (T2D) is a chronic metabolic disease that is highly prevalent in the United Arab Emirates (UAE). This study aimed to assess the cost-consequences of adding gliclazide modified release (MR) to metformin in patients with inadequate glycaemic control on metformin alone and of switching patients currently receiving a combination of sitagliptin and metformin to a combination of gliclazide MR and metformin.

Methods

We developed a cost-consequences decision-tree model comparing gliclazide MR and sitagliptin as second-line add-ons to metformin. Based on 2014-2023 Dubai Real World Claims Database data, the model estimated health outcomes (number of patients reaching HbA_1c targets of < 7% and ≤ 6.5% and cardiovascular [CV] events, i.e. myocardia

SUBMITTER: Farghaly M 

PROVIDER: S-EPMC12738661 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature